Quick Answer
Oruka Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $46.94 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed a decrease of -23.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $9.92 million | Q3 2010: $7.91 million | Q1 2011: $5.09 million | Q2 2011: $7.46 million | Q3 2011: $5.75 million | Q1 2012: $4.23 million | Q2 2012: $3.18 million | Q3 2012: $3.08 million | Q1 2013: $3.54 million | Q2 2013: $20.37 million | Q3 2013: $18.63 million | Q1 2014: $21.20 million | Q2 2014: $19.38 million | Q3 2014: $17.25 million | Q1 2015: $12.18 million | Q2 2015: $44.09 million | Q3 2015: $41.48 million | Q1 2016: $29.72 million | Q2 2016: $14.38 million | Q3 2016: $8.10 million | Q1 2017: $6.17 million | Q2 2017: $9.10 million | Q3 2017: $8.14 million | Q4 2017: $8.70 million | Q1 2018: $12.10 million | Q2 2018: $9.64 million | Q3 2018: $8.06 million | Q1 2019: $8.01 million | Q2 2019: $9.97 million | Q3 2019: $9.65 million | Q1 2020: $6.67 million | Q2 2020: $11.04 million | Q3 2020: $51.10 million | Q1 2021: $66.93 million | Q2 2021: $63.20 million | Q3 2021: $58.31 million | Q1 2022: $49.06 million | Q2 2022: $46.44 million | Q3 2022: $43.94 million | Q1 2023: $40.85 million | Q2 2023: $40.16 million | Q3 2023: $38.49 million | Q4 2023: $37.43 million | Q1 2024: $35.90 million | Q2 2024: $33.28 million | Q3 2024: $410.88 million | Q1 2025: $83.57 million | Q2 2025: $65.40 million | Q3 2025: $91.25 million.
- Over the full 17 years of available data (2009 to 2025), Oruka Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 504.6%.
- Historical annual values: Fiscal year 2025: $46.94 million | Fiscal year 2024: $61.58 million | Fiscal year 2023: $37.43 million | Fiscal year 2022: $42.45 million | Fiscal year 2021: $53.36 million | Fiscal year 2020: $49.07 million | Fiscal year 2019: $8.36 million | Fiscal year 2018: $6.61 million | Fiscal year 2017: $8.70 million | Fiscal year 2016: $7.40 million | Fiscal year 2015: $38.80 million | Fiscal year 2014: $15.35 million | Fiscal year 2013: $16.76 million | Fiscal year 2012: $2.92 million | Fiscal year 2011: $5.94 million | Fiscal year 2010: $7.03 million | Fiscal year 2009: $7.76 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: